Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis
Background and purpose Mitoxantrone (MX) (Novantrone®) is approved in Canada for certain refractory cancers and acute non-lymphocytic leukemias. It has FDA approval as an immunomodulatory agent for use in secondary progressive multiple sclerosis (SPMS). The general aim of this study is to evaluate t...
Gespeichert in:
| Veröffentlicht in: | Clinical Medicine Insights: Therapeutics 2011-01, Vol.2011 (3), p.449-458 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 458 |
|---|---|
| container_issue | 3 |
| container_start_page | 449 |
| container_title | Clinical Medicine Insights: Therapeutics |
| container_volume | 2011 |
| creator | Namaka, M.P. Turcotte, D.A. Klowak, M. Leong, C.M. Grossberndt, A. Le Dorze, J-A. Prout, M.E. Andresen, S. Vuong, L. Melanson, M.J. Frost, E.E. Doupe, M. |
| description | Background and purpose
Mitoxantrone (MX) (Novantrone®) is approved in Canada for certain refractory cancers and acute non-lymphocytic leukemias. It has FDA approval as an immunomodulatory agent for use in secondary progressive multiple sclerosis (SPMS). The general aim of this study is to evaluate the efficacy, safety, and tolerability of MX in SPMS.
Experimental approach
A single-centre, open-label, non-randomized study was conducted in patients with a ≥6 month history of SPMS. The primary parameters used to assess efficacy and safety were EDSS scores and the multiple-gated acquisition scan (MUGA) scores, respectively.
Key results
The MX-treatment group experienced a high dropout rate due to significantly reduced ventricular ejection fraction. EDSS scores from baseline to follow-up revealed no statistical difference between active control and MX-treatment groups. Conclusion: MX treatment may not slow disease progression in certain forms of SPMS and may be associated with a high risk of cardiotoxicity. |
| doi_str_mv | 10.4137/CMT.S7586 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1038333565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A427008420</galeid><airiti_id>P20160603001_201112_201606030019_201606030019_449_458</airiti_id><sage_id>10.4137_CMT.S7586</sage_id><sourcerecordid>A427008420</sourcerecordid><originalsourceid>FETCH-LOGICAL-a505t-7675706a3af3e4c0850c405d6a59a7221eeaa11ba23d8fa1c3e3da5f8c33ea3b3</originalsourceid><addsrcrecordid>eNptUdtqGzEQXUoLDWke-gcLhUIf1tVltZeXQnDTNmDTgFPIU8RYO-tMkFeupC3131epQ203QQiNZs6cmTmTZW85m5Rc1h-n8-vJolZN9SI74bxuC6Xam5cH9uvsLIR7xpgQZVXJ9iS7vQBvt_mcovsNQ_RuwOJy6EaDXT4F35FLATIUt_lnjGhi8tOQL9C4oQO_za-8W3kMgX5hPh9tpI3FfGEsehcovMle9WADnj2-p9mPLxfX02_F7PvXy-n5rADFVCzqqlY1q0BCL7E0rFHMlEx1FagWaiE4IgDnSxCya3rgRqLsQPWNkRJBLuVp9m7Hu_Hu54gh6ns3-iGV1JzJRkqpKrVHrcCipqF30YNZUzD6vBQ1Y00pWEJNnkGl0-Ga0tjYU_IfJbw_SLhDsPEuODtGckM4Bn7YAU0SJ3js9cbTOqmYmtQPG9Rpg_rvBvekAVZ4OM1T4Kcd0NISfYTw2Cn8I3dA-r-gAW3cWoumflBltiMA8hRpX-tKMF6xiknGuE4250IfuNrjT1mmqxr5B5JqxN0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1038333565</pqid></control><display><type>article</type><title>Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis</title><source>Alma/SFX Local Collection</source><creator>Namaka, M.P. ; Turcotte, D.A. ; Klowak, M. ; Leong, C.M. ; Grossberndt, A. ; Le Dorze, J-A. ; Prout, M.E. ; Andresen, S. ; Vuong, L. ; Melanson, M.J. ; Frost, E.E. ; Doupe, M.</creator><creatorcontrib>Namaka, M.P. ; Turcotte, D.A. ; Klowak, M. ; Leong, C.M. ; Grossberndt, A. ; Le Dorze, J-A. ; Prout, M.E. ; Andresen, S. ; Vuong, L. ; Melanson, M.J. ; Frost, E.E. ; Doupe, M.</creatorcontrib><description>Background and purpose
Mitoxantrone (MX) (Novantrone®) is approved in Canada for certain refractory cancers and acute non-lymphocytic leukemias. It has FDA approval as an immunomodulatory agent for use in secondary progressive multiple sclerosis (SPMS). The general aim of this study is to evaluate the efficacy, safety, and tolerability of MX in SPMS.
Experimental approach
A single-centre, open-label, non-randomized study was conducted in patients with a ≥6 month history of SPMS. The primary parameters used to assess efficacy and safety were EDSS scores and the multiple-gated acquisition scan (MUGA) scores, respectively.
Key results
The MX-treatment group experienced a high dropout rate due to significantly reduced ventricular ejection fraction. EDSS scores from baseline to follow-up revealed no statistical difference between active control and MX-treatment groups. Conclusion: MX treatment may not slow disease progression in certain forms of SPMS and may be associated with a high risk of cardiotoxicity.</description><identifier>ISSN: 1179-559X</identifier><identifier>EISSN: 1179-559X</identifier><identifier>DOI: 10.4137/CMT.S7586</identifier><language>eng</language><publisher>London, England: Libertas Academica</publisher><subject>Development and progression ; Drug approval ; Mitoxantrone hydrochloride ; Multiple sclerosis</subject><ispartof>Clinical Medicine Insights: Therapeutics, 2011-01, Vol.2011 (3), p.449-458</ispartof><rights>2011 SAGE Publications.</rights><rights>COPYRIGHT 2011 Sage Publications Ltd. (UK)</rights><rights>Copyright Libertas Academica Ltd 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a505t-7675706a3af3e4c0850c405d6a59a7221eeaa11ba23d8fa1c3e3da5f8c33ea3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Namaka, M.P.</creatorcontrib><creatorcontrib>Turcotte, D.A.</creatorcontrib><creatorcontrib>Klowak, M.</creatorcontrib><creatorcontrib>Leong, C.M.</creatorcontrib><creatorcontrib>Grossberndt, A.</creatorcontrib><creatorcontrib>Le Dorze, J-A.</creatorcontrib><creatorcontrib>Prout, M.E.</creatorcontrib><creatorcontrib>Andresen, S.</creatorcontrib><creatorcontrib>Vuong, L.</creatorcontrib><creatorcontrib>Melanson, M.J.</creatorcontrib><creatorcontrib>Frost, E.E.</creatorcontrib><creatorcontrib>Doupe, M.</creatorcontrib><title>Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis</title><title>Clinical Medicine Insights: Therapeutics</title><description>Background and purpose
Mitoxantrone (MX) (Novantrone®) is approved in Canada for certain refractory cancers and acute non-lymphocytic leukemias. It has FDA approval as an immunomodulatory agent for use in secondary progressive multiple sclerosis (SPMS). The general aim of this study is to evaluate the efficacy, safety, and tolerability of MX in SPMS.
Experimental approach
A single-centre, open-label, non-randomized study was conducted in patients with a ≥6 month history of SPMS. The primary parameters used to assess efficacy and safety were EDSS scores and the multiple-gated acquisition scan (MUGA) scores, respectively.
Key results
The MX-treatment group experienced a high dropout rate due to significantly reduced ventricular ejection fraction. EDSS scores from baseline to follow-up revealed no statistical difference between active control and MX-treatment groups. Conclusion: MX treatment may not slow disease progression in certain forms of SPMS and may be associated with a high risk of cardiotoxicity.</description><subject>Development and progression</subject><subject>Drug approval</subject><subject>Mitoxantrone hydrochloride</subject><subject>Multiple sclerosis</subject><issn>1179-559X</issn><issn>1179-559X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>BENPR</sourceid><recordid>eNptUdtqGzEQXUoLDWke-gcLhUIf1tVltZeXQnDTNmDTgFPIU8RYO-tMkFeupC3131epQ203QQiNZs6cmTmTZW85m5Rc1h-n8-vJolZN9SI74bxuC6Xam5cH9uvsLIR7xpgQZVXJ9iS7vQBvt_mcovsNQ_RuwOJy6EaDXT4F35FLATIUt_lnjGhi8tOQL9C4oQO_za-8W3kMgX5hPh9tpI3FfGEsehcovMle9WADnj2-p9mPLxfX02_F7PvXy-n5rADFVCzqqlY1q0BCL7E0rFHMlEx1FagWaiE4IgDnSxCya3rgRqLsQPWNkRJBLuVp9m7Hu_Hu54gh6ns3-iGV1JzJRkqpKrVHrcCipqF30YNZUzD6vBQ1Y00pWEJNnkGl0-Ga0tjYU_IfJbw_SLhDsPEuODtGckM4Bn7YAU0SJ3js9cbTOqmYmtQPG9Rpg_rvBvekAVZ4OM1T4Kcd0NISfYTw2Cn8I3dA-r-gAW3cWoumflBltiMA8hRpX-tKMF6xiknGuE4250IfuNrjT1mmqxr5B5JqxN0</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Namaka, M.P.</creator><creator>Turcotte, D.A.</creator><creator>Klowak, M.</creator><creator>Leong, C.M.</creator><creator>Grossberndt, A.</creator><creator>Le Dorze, J-A.</creator><creator>Prout, M.E.</creator><creator>Andresen, S.</creator><creator>Vuong, L.</creator><creator>Melanson, M.J.</creator><creator>Frost, E.E.</creator><creator>Doupe, M.</creator><general>Libertas Academica</general><general>SAGE Publishing</general><general>SAGE Publications</general><general>Sage Publications Ltd. (UK)</general><general>Sage Publications Ltd</general><scope>188</scope><scope>AFRWT</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AYAGU</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20110101</creationdate><title>Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis</title><author>Namaka, M.P. ; Turcotte, D.A. ; Klowak, M. ; Leong, C.M. ; Grossberndt, A. ; Le Dorze, J-A. ; Prout, M.E. ; Andresen, S. ; Vuong, L. ; Melanson, M.J. ; Frost, E.E. ; Doupe, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a505t-7675706a3af3e4c0850c405d6a59a7221eeaa11ba23d8fa1c3e3da5f8c33ea3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Development and progression</topic><topic>Drug approval</topic><topic>Mitoxantrone hydrochloride</topic><topic>Multiple sclerosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Namaka, M.P.</creatorcontrib><creatorcontrib>Turcotte, D.A.</creatorcontrib><creatorcontrib>Klowak, M.</creatorcontrib><creatorcontrib>Leong, C.M.</creatorcontrib><creatorcontrib>Grossberndt, A.</creatorcontrib><creatorcontrib>Le Dorze, J-A.</creatorcontrib><creatorcontrib>Prout, M.E.</creatorcontrib><creatorcontrib>Andresen, S.</creatorcontrib><creatorcontrib>Vuong, L.</creatorcontrib><creatorcontrib>Melanson, M.J.</creatorcontrib><creatorcontrib>Frost, E.E.</creatorcontrib><creatorcontrib>Doupe, M.</creatorcontrib><collection>Airiti Library</collection><collection>Sage Journals GOLD Open Access 2024</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Australia & New Zealand Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Clinical Medicine Insights: Therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Namaka, M.P.</au><au>Turcotte, D.A.</au><au>Klowak, M.</au><au>Leong, C.M.</au><au>Grossberndt, A.</au><au>Le Dorze, J-A.</au><au>Prout, M.E.</au><au>Andresen, S.</au><au>Vuong, L.</au><au>Melanson, M.J.</au><au>Frost, E.E.</au><au>Doupe, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis</atitle><jtitle>Clinical Medicine Insights: Therapeutics</jtitle><date>2011-01-01</date><risdate>2011</risdate><volume>2011</volume><issue>3</issue><spage>449</spage><epage>458</epage><pages>449-458</pages><issn>1179-559X</issn><eissn>1179-559X</eissn><abstract>Background and purpose
Mitoxantrone (MX) (Novantrone®) is approved in Canada for certain refractory cancers and acute non-lymphocytic leukemias. It has FDA approval as an immunomodulatory agent for use in secondary progressive multiple sclerosis (SPMS). The general aim of this study is to evaluate the efficacy, safety, and tolerability of MX in SPMS.
Experimental approach
A single-centre, open-label, non-randomized study was conducted in patients with a ≥6 month history of SPMS. The primary parameters used to assess efficacy and safety were EDSS scores and the multiple-gated acquisition scan (MUGA) scores, respectively.
Key results
The MX-treatment group experienced a high dropout rate due to significantly reduced ventricular ejection fraction. EDSS scores from baseline to follow-up revealed no statistical difference between active control and MX-treatment groups. Conclusion: MX treatment may not slow disease progression in certain forms of SPMS and may be associated with a high risk of cardiotoxicity.</abstract><cop>London, England</cop><pub>Libertas Academica</pub><doi>10.4137/CMT.S7586</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1179-559X |
| ispartof | Clinical Medicine Insights: Therapeutics, 2011-01, Vol.2011 (3), p.449-458 |
| issn | 1179-559X 1179-559X |
| language | eng |
| recordid | cdi_proquest_journals_1038333565 |
| source | Alma/SFX Local Collection |
| subjects | Development and progression Drug approval Mitoxantrone hydrochloride Multiple sclerosis |
| title | Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A14%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20Mitoxantrone-Induced%20Cardiotoxicity%20Detected%20in%20Secondary%20Progressive%20Multiple%20Sclerosis&rft.jtitle=Clinical%20Medicine%20Insights:%20Therapeutics&rft.au=Namaka,%20M.P.&rft.date=2011-01-01&rft.volume=2011&rft.issue=3&rft.spage=449&rft.epage=458&rft.pages=449-458&rft.issn=1179-559X&rft.eissn=1179-559X&rft_id=info:doi/10.4137/CMT.S7586&rft_dat=%3Cgale_proqu%3EA427008420%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1038333565&rft_id=info:pmid/&rft_galeid=A427008420&rft_airiti_id=P20160603001_201112_201606030019_201606030019_449_458&rft_sage_id=10.4137_CMT.S7586&rfr_iscdi=true |